Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Finished

PRIME PRodrug technology for Immunotherapy-priming via patient-friendly at-home MEtronomic dosing

Coordinator
Universitaetsklinikum Aachen, Germany
Runs
1 October 2023 to 31 March 2025
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101138100

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy holds great promise for curative cancer treatment. While immune checkpoint inhibitors can induce complete and long-term cures, the percentage of patients responding to immunotherapy remains to be low. Combining immunotherapy with chemotherapeutic drugs that induce immunogenic cell death (ICD) is among the most promising strategies to potentiate antitumor immune responses. Chemotherapeutics are clinically typically administered via intravenous infusion, once every couple of weeks, at high doses.

Metronomic dosing is based on the application of chemotherapy drugs at high frequency and low doses, and it is gaining increasing interest to potentiate chemo-immunotherapy responses. However, high-frequency low-dose chemotherapy administration in the clinic via intravenous infusion is pragmatically undoable and economically not feasible. At-home administration via oral ingestion or subcutaneous self-injection is impossible, because of the side effect spectrum of chemotherapeutic drugs.

In the PRIME project, we aim to establish PRodrug technology for Immunotherapy-priming via patient-friendly at-home MEtronomic dosing. Prodrugs have assisted in improving drug performance for over a century now, and they are widely employed in pharmaceutical industry and clinical practice, with approximately 10% of new drug approvals technically being prodrugs. We will set out to establish a synthetic and formulation strategy to produce a novel immunogenic prodrug platform, and upon subcutaneous metronomic dosing, we will evaluate the preclinical performance of our prodrugs as monotherapy and in combination with immunotherapy in breast and prostate cancer mouse models.

We anticipate that exploiting the technological and socio-economic potential of PRIME will unlock new avenues towards at-home cancer treatment opportunities with enhanced therapeutic outcomes and improved patient quality-of-life.

Topics

Who is involved

OrganisationCityCountryRole
Universitaetsklinikum AachenAachenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI